Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 3;11(5):1385.
doi: 10.3390/jcm11051385.

Pharmacological Treatment in Presbyopia

Andrzej Grzybowski  1   2 , Varis Ruamviboonsuk  3
Affiliations
Review

Pharmacological Treatment in Presbyopia

Andrzej Grzybowski et al. J Clin Med. .

Abstract

Pharmacological treatment of presbyopia may be an alternative for those who want a spectacle-free scenario and an easy-to-use method with lower risk of irreversible ocular adverse events. There are two main agents, miotics and lens softeners, investigated as agents for the pharmacological treatment. Miotic agents treat presbyopia by creating a pinhole effect which may increase the depth of focus at all working distances. The miotic agents have been studied for application to only one eye for monovision or both eyes. Their effect is temporary with common adverse events, such as headache and dim vision at nighttime, with no known long-term safety and efficacy. There have been studies on the miotic agents in combination with other agents for additive treatment effects or lessening adverse events, however, these combination effects are not clear. Lens softeners increase the elasticity of the lens, which is targeted at one of the etiologic mechanisms of presbyopia. There is only one lens softener being investigated in only a few trials. The results were inconclusive. The recent approval of 1.25% pilocarpine for treatment of presbyopia by the US FDA may be an important milestone for investigation of real-world data of pharmacological treatment of presbyopia.

Keywords: correction; medical; pharmacological; presbyopia; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Pharmacological treatment for presbyopia mechanism of action.
See this image and copyright information in PMC

References

    1. Wolffsohn J.S., Davies L.N. Presbyopia: Effectiveness of correction strategies. Prog. Retin. Eye Res. 2019;68:124–143. doi: 10.1016/j.preteyeres.2018.09.004. - DOI - PubMed
    1. Holden B.A., Fricke T.R., Wilson D.A., Jong M., Naidoo K.S., Sankaridurg P., Wong T.Y., Naduvilath T.J., Resnikoff S. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology. 2016;123:1036–1042. doi: 10.1016/j.ophtha.2016.01.006. - DOI - PubMed
    1. Strenk S.A., Strenk L.M., Koretz J.F. The mechanism of presbyopia. Prog. Retin. Eye Res. 2005;24:379–393. doi: 10.1016/j.preteyeres.2004.11.001. - DOI - PubMed
    1. Michael-Titus A., Revest P., Shortland P. The Visual System. In: Michael-Titus A., Revest P., Shortland P., editors. The Nervous System. Elsevier; Amsterdam, The Netherlands: 2010. pp. 121–140.
    1. Weikert M.P. Update on bimanual microincisional cataract surgery. Curr. Opin. Ophthalmol. 2006;17:62–67. doi: 10.1097/01.icu.0000193069.32369.e1. - DOI - PubMed

LinkOut - more resources